PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC

Lin Chingwen; Lin Peiying; Yang Panchyr

首页> 外文期刊>Respirology : >PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC

【24h】

PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC

机译：NSCLC中抗代谢物化疗药物抗PD-1 / PD-L1治疗的启动

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Respirology :》 |2018年第2期|共1页
作者
Lin Chingwen; Lin Peiying; Yang Panchyr;
展开▼
作者单位

Acad Sinica Taipei Taiwan;

Natl Taiwan Univ Hosp Natl Ctr Excellence Clin Trials Taipei Taiwan;

Natl Taiwan Univ Hosp &

Coll Med Dept Internal Med Taipei Taiwan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC [J] . Lin Chingwen, Lin Peiying, Yang Panchyr Respirology : . 2018,第Suppla2期

机译：NSCLC中抗代谢物化疗药物抗PD-1 / PD-L1治疗的启动
2. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis [J] . Abdel-Rahman Omar Critical reviews in oncology/hematology . 2016,第Null期

机译：抗PD-1 / PD-L1药物治疗的NSCLC患者PD-L1表达与预后的相关性：荟萃分析
3. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy [J] . Kim A. Brogden, Deepak Parashar, Andrea R. Hallier, BMC Cancer . 2018,第1期

机译：NSCLC患者的基因组学既可以肯定PD-L1的表达，又可以预测其对抗PD-1免疫疗法的临床反应
4. Useful Combination Therapy of Anti-angiogenic Agent with Chemotherapeutic Agents or RadionuclideTherapy for Cancer Treatment [C] . Sun-Ju Choi, So-Young Lee, Young-Don Hong Controlled Release Society Annual Meeting and Exposition . 2007

机译：抗血管生成剂与化学治疗剂或放射性核素的有效组合疗法可用于癌症治疗
5. Combinatorial Bioengineered ncRNA Agents for Multi-Targeting in NSCLC [D] . Petrek, Hannah. 2019

机译：组合生物工程NCRNA剂在NSCLC中的多靶向
6. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients [O] . Shaodong Hong, Nan Chen, Wenfeng Fang, 2016

机译：EML4-ALK融合蛋白对PD-L1的上调介导ALK阳性NSCLC的免疫逃逸：对ALK-TKI敏感和耐药的NSCLC患者可选的抗PD-1 / PD-L1免疫疗法的意义
7. PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC [O] . 2018

机译：NSCLC中抗代谢物化疗药物抗PD-1 / PD-L1治疗的启动
8. Interaction Between Chemotherapeutic Agents and Biological Processes in Isolated Mammalian Cells. Coordinated Programme on Improvement in Radiotherapy of Cancer Using Modifiers of Radiosensitivity of Cells. Final Report for the Pe [R] . Djordjevic, O. 1982

机译：分离的哺乳动物细胞中化学治疗剂与生物过程的相互作用。利用细胞放射敏感性改良剂改善癌症放射治疗的协调计划。 pe的最终报告

PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC

著录项

引文网络

相似文献

相关主题

期刊订阅